Latest revenue
$58.3M
as of 2026-03-31
Latest net income
$-30.4M
as of 2026-03-31
Net margin
-52.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $903.6M
- Enterprise value
- $903.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $18.31
- 52-wk low
- $3.92
- Beta
- —
- Shares out
- 79.8M
5-year trend
What this company does
Item 1. Business Overview We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA®, VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK®, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan is the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years, and has shown rapid, potent, and durable anti-secretory effects. Vonoprazan has also demonstrated clinical benefits over the current standard of care as…
AI summary unavailable — showing raw filing excerpt
Generated from PHAT's filing dated 2024-03-07
Key risks
Item 1A. Risk Factors You should carefully consider the following risk factors, together with the other information contained in this annual report on Form 10-K, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline.…
AI summary unavailable — showing raw filing excerpt
Generated from PHAT's filing dated 2024-03-07
Profitability
Gross margin
87.1%
1.8%Operating margin
-91.4%
81.8%Net margin
-126.3%
79.1%Return on equity
50.5%
61.7%Return on assets
-85.4%
3.4%Leverage
Debt / equity
-1.59×
36.1%Long-term debt / equity
-0.48×
39.9%Debt / assets
269.1%
61.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $58.3M | +104.4% | $-30.4M | +67.8% | -52.1% |
Q4 2025 2025-12-31 | $57.6M | +94.1% | $-21.1M | +71.6% | -36.7% |
Q3 2025 2025-09-30 | $49.5M | +202.7% | $-30.0M | +65.0% | -60.5% |
Q2 2025 2025-06-30 | $39.5M | +439.4% | $-75.8M | +17.1% | -191.9% |
Q1 2025 2025-03-31 | $28.5M | +1391.6% | $-94.3M | -13.8% | -330.7% |
Q4 2024 2024-12-31 | $29.7M | — | $-74.5M | — | -251.0% |
Q3 2024 2024-09-30 | $16.4M | — | $-85.6M | -97.9% | -523.3% |
Q2 2024 2024-06-30 | $7.3M | — | $-91.4M | -123.2% | -1248.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on PHAT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$26.8K
Net activity
−$26.8K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PHAT
Institutional value
$328.7M
Total shares held
31.2M
Distinct holders
81
-90 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Medicxi Ventures Management (Jersey) Ltd | 7.5M | $82.9M | +0 (+0.0%) | No change |
| 2 | Invesco Ltd. | 4.3M | $48.0M | +401.6K (+10.2%) | Added |
| 3 | BlackRock, Inc. | 4.1M | $45.1M | +506.4K (+14.2%) | Added |
| 4 | Carlyle Group Inc. | 3.5M | $38.8M | +0 (+0.0%) | No change |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $28.7M | — | New |
| 6 | Ensign Peak Advisors, Inc | 1.6M | $18.1M | -724.2K (-30.8%) | Trimmed |
| 7 | WASATCH ADVISORS LP | 1.3M | $14.9M | +9.2K (+0.7%) | Added |
| 8 | FRANKLIN RESOURCES INC | 994.5K | $11.0M | — | New |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 666.0K | $7.4M | — | New |
| 10 | UBS Group AG | 360.4K | $4.0M | +56.0K (+18.4%) | Added |
| 11 | VANGUARD FIDUCIARY TRUST CO | 338.7K | $3.8M | — | New |
| 12 | JPMORGAN CHASE & CO | 287.4K | $3.0M | -9.3K (-3.1%) | Trimmed |
| 13 | Simplify Asset Management Inc. | 262.4K | $2.9M | -59.5K (-18.5%) | Trimmed |
| 14 | Avidity Partners Management LP | 249.4K | $2.8M | +43.3K (+21.0%) | Added |
| 15 | Bank of New York Mellon Corp | 124.0K | $1.4M | +1.1K (+0.9%) | Added |
| 16 | Nuveen, LLC | 117.3K | $1.3M | +8.5K (+7.8%) | Added |
| 17 | Stratos Wealth Partners, LTD. | 100.0K | $1.1M | +49.7K (+98.8%) | Added |
| 18 | Swiss National Bank | 92.6K | $1.0M | +8.6K (+10.2%) | Added |
| 19 | Russell Investments Group, Ltd. | 85.7K | $951.9K | +79.0K (+1189.6%) | Added |
| 20 | HUSSMAN STRATEGIC ADVISORS, INC. | 84.0K | $933.2K | -63.0K (-42.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PHAT's latest filing finishes processing.